| Spotlight |
 |
|
In this episode, two oncology analysts share their insights from the ASCO show floor, while talking through the readouts that excited them most.
|
| Latest news |
|
|
The Regeneron-partnered biotech is currently progressing its lead asset, zolucatetide, in desmoid tumours.
|
|
|
According to the agreement, Pfizer will become one of the first pharmaceutical companies to access Chai’s newly revealed Chai-3 model.
|
|
|
Keytruda continues to shine in solid tumours, and other Merck & Co assets signal designs to address Keytruda's upcoming exclusivity loss.
|
|
|
The FDA's decision follows data from a Phase Ib study on salanersen.
|
|
|
If enacted, lawmakers will hold the right to monitor and restrict American companies from signing certain deals with Chinese entities.
|
|
|
|
